Pharmatech Associates

Bringing a drug or medical device to market involves regulatory requirements, quality systems, and manufacturing processes that are complex and unforgiving of mistakes. As experienced pharmaceutical manufacturing consultants, Pharmatech Associates helps you anticipate what regulators expect, close gaps before they become problems, and move through approval with confidence—saving you the time, cost, and risk of figuring it out alone.

Yes. Documentation gaps are one of the most common reasons filings get delayed or rejected. Pharmatech can quickly assess where you stand, identify what’s missing, and help you build the records and quality systems you need to satisfy regulators—often starting in a matter of days.

Absolutely. The earlier you involve us, the more we can help you avoid costly missteps. We support startups and emerging companies in building quality systems, preparing for regulatory filings, and getting products ready to discuss with the FDA—so you’re set up for success from the start.

Being out of compliance can be expensive and disruptive. A rejected drug filing can pause your review cycle, and a warning letter can lead to a consent decree that costs millions in consultants, legal teams, and lost time. Pharmatech helps you address compliance issues quickly and build systems that keep you on the right side of regulators going forward.

We pride ourselves on being nimble. When timelines are tight, we can often begin within days—putting the right experts on your project so you don’t lose momentum at a critical moment.

Yes. Pharmatech Associates is a global firm supporting clients across North America, Europe, Japan, and beyond. We’re especially experienced in US market entry, including helping international companies navigate the requirements of multiple regulatory bodies at once.

We’re not just a vendor—we’re a partner. As a USP company, we bring nearly 30 years of experience, deep relationships with former FDA inspectors and regulators, and dedicated project management on every engagement. We put the right resources in the right places and stay with you through every step of the process.

We provide support across quality and compliance, regulatory affairs, remediation, and CMC, with specialized expertise for biologics and TIDES, combination products, and small molecules. Whether you’re a startup preparing for your first filing or an established company strengthening your quality systems, we tailor our solutions to your needs.

Yes. Every engagement includes dedicated project management, so nothing falls through the cracks and you always know where your project stands. We see ourselves as a long-term partner, not a one-time fix.

This is a challenge many established companies face. Pharmatech Associates can step in with the industry expertise your team needs, help document and standardize your processes, and transform your quality system into one that aligns with best practices—so institutional knowledge doesn’t walk out the door.

Every engagement is scoped to your specific needs, so cost depends on the size and complexity of your project. We’re mindful that many of our clients—especially startups and growing companies—are cost-sensitive, so we focus on putting the right resources in the right places rather than over-staffing. Reach out and we’ll talk through your project and what an engagement might look like.

Yes. Walking into an inspection unprepared can cost you time and money, and the uncertainty alone is stressful. We help you understand what reviewers expect, identify and close gaps in advance, and approach your inspection with confidence instead of guesswork.

We can. A rejected filing kicks you out of the review cycle, but it doesn’t have to derail your product. Our experts will help you understand what went wrong, correct the underlying issues, and rebuild your path back into the process.

As involved as you need us to be. Some clients want hands-on partners embedded in their processes; others need targeted guidance at key milestones. We adapt to how you work.

We partner with startups, small and mid-sized companies, and established life science organizations developing drugs, biologics, and medical devices.